Moderna Forms Oncology Collaboration With Carisma Therapeutics
January 10 2022 - 7:16AM
Dow Jones News
By Colin Kellaher
Moderna Inc. on Monday said it will collaborate with privately
held biopharmaceutical company Carisma Therapeutics Inc. to
discover, develop and commercialize in-vivo engineered chimeric
antigen receptor monocyte therapeutics for the treatment of
cancer.
Moderna, the Cambridge, Mass., biotechnology company best known
for its Covid-19 vaccine, said the collaboration expands its
oncology pipeline with a differentiated in-vivo cell-therapy
approach.
Moderna said it will make a $45 million upfront cash payment to
Carisma, which will also receive an investment in the form of a $35
million convertible note. Carisma also will receive research
funding and is eligible to receive development, regulatory and
commercial milestone payments, along with royalties on sales of any
products that result from the collaboration.
Moderna, which has the option to nominate up to a dozen targets,
said Carisma will be responsible for the discovery and optimization
of development candidates, while Moderna will lead the clinical
development and commercialization activities.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 10, 2022 07:01 ET (12:01 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024